ALT — Altimmune, Inc.

Is ALT overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of August 19, 2026

Altimmune, Inc. (ALT) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $2.97. The rating moved from Neutral to Oversold on August 19, 2026.

See all oversold Healthcare stocks →

AI analysis

Altimmune, Inc. (ALT) is a clinical-stage biotechnology company whose near-term equity performance will be driven primarily by clinical readouts, partnering activity, and financing outcomes. The firm sits in a favorable macro sector for biologics and CDMO demand, but the stock remains sensitive to trial results and cash-runway dynamics.

Key factors

  • Altimmune, Inc. (ALT) is a clinical-stage biotech with limited or no recurring commercial revenue; valuation reflects high optionality on pipeline readouts.
  • Company progress and near-term value catalysts are centered on clinical trial results, regulatory milestones, and potential partnership/licensing activity.
  • Sector tailwinds for biologics, CDMO/CRO demand, and broader healthcare innovation create a favorable backdrop that could indirectly support program development or partnering opportunities.
  • Market sentiment is muted with low retail/social buzz; recent macro tone is modestly risk-on which can help small-cap biotech liquidity in the near term.
  • Balance sheet and cash runway uncertainty (typical for peers) increase the likelihood of financing-related dilution absent clear near-term positive readouts.
  • Relative illiquidity and tight float can amplify volatility around news events, producing large short-term moves absent fundamental change.

Risks

  • Clinical trial failures or disappointing safety/efficacy data that materially reduce program valuations.
  • Need for additional capital leading to dilution or unfavorable financing terms.
  • Regulatory setbacks or slower-than-expected review/approval timelines.
  • Competition from larger, better-funded biopharma entrants or alternative therapeutic approaches.
  • Limited commercialization experience and reliance on partners or third parties for late-stage development and manufacturing.
  • Broader market/interest-rate driven risk that compresses small-cap biotech multiples and reduces risk-appetite.

See today's live rating, score and targets

Members see the live hourly rating for ALT — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.